Virtus Biotech Clinical Trials ETF
16 hedge funds and large institutions have $1.27M invested in Virtus Biotech Clinical Trials ETF in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
6% less funds holding
Funds holding: 17 → 16 (-1)
7.92% less ownership
Funds ownership: 22.31% → 14.39% (-7.9%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
52% less capital invested
Capital invested by funds: $2.67M → $1.27M (-$1.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$40.5K |
| 2 |
Morgan Stanley
New York
|
+$38.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$23K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$7.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$881K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$301K |
| 3 |
LPL Financial
San Diego,
California
|
-$14.6K |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$6.73K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$6.66K |
BBC Hedge Fund Activity: Q3 2023 in Review
16 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2023, worth a combined $1.27M — down 52% from $2.67M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BBC and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, adding an estimated $40.5K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $881K sold.
- 16 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $1.27M of Virtus Biotech Clinical Trials ETF stock for Q3 2023, down 52% quarter-over-quarter.
- 1 fund opened new Virtus Biotech Clinical Trials ETF positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2023 was Citadel Advisors, an estimated $40.5K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2023 was Susquehanna International Group, an estimated $881K sold.
Based on aggregated 13F filings for Q3 2023.